1. Home
  2. SOPH vs CMPX Comparison

SOPH vs CMPX Comparison

Compare SOPH & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

HOLD

Current Price

$8.79

Market Cap

462.3M

Sector

Health Care

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.51

Market Cap

408.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOPH
CMPX
Founded
2011
2014
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.3M
408.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SOPH
CMPX
Price
$8.79
$2.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$7.50
$14.57
AVG Volume (30 Days)
474.9K
3.3M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.09
N/A
Revenue Next Year
$19.57
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.10
$1.61
52 Week High
$8.84
$6.88

Technical Indicators

Market Signals
Indicator
SOPH
CMPX
Relative Strength Index (RSI) 71.28 61.93
Support Level $4.63 $1.68
Resistance Level N/A $2.47
Average True Range (ATR) 0.44 0.14
MACD 0.09 0.03
Stochastic Oscillator 84.06 84.62

Price Performance

Historical Comparison
SOPH
CMPX

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: